Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Material
Type of Publication
Consortium
Language
  • 1
    UID:
    (DE-101)967233828
    Format: 181 Bl. , Ill., graph. Darst. , 30 cm
    Note: Freiburg (Breisgau), Univ., Diss., 2003 (Nur beschränkt für den Austausch)
    Language: English
    Keywords: Hochschulschrift
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    UID:
    (DE-627)1173506039
    Format: 181 Bl. , Ill., graph. Darst.
    Note: Freiburg i. Br., Univ., Diss., 2003
    Language: English
    Keywords: Hochschulschrift
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    UID:
    (DE-603)396803857
    Format: Online-Ressource
    Content: Zusammenfassung: Activating mutations of Fms-like tyrosine kinase 3 (FLT3) are among the most frequent alterations in acute myeloid leukemia (AML). Two distinct types of mutations have been described: internal duplication of the juxtamembraneous domain (ITD) and point mutations of the tyrosine kinase domain (TKD). Although both mutations lead to constitutive FLT3 signaling, only FLT3-ITD strongly activates STAT5. In a murine transplantation model, FLT3-ITD induces a myeloproliferative neoplasm (MPN), while FLT3-TKD leads to a lymphoid disease with significantly longer latency. In the present study it should be examined, to which extent STAT5 has a role for the induction and phenotype of the MPN in the murine model. Furthermore, it should be addressed whether cell-type specific STAT5 signaling in myeloid, but not lymphoid progenitors is responsible for the FLT3-ITD-mediated myeloid expansion in mice and humans.In an initial in vitro experiment, STAT5 was found to be critical for the colony formation of FLT3-ITD+, but not FLT3-TKD+ fetal liver cells. These results were further confirmed in a conditional murine knockout model of Stat5, where the development of a myeloproliferative disease by FLT3-ITD is also dependent on STAT5. In case of the FLT3-TKD-induced disease, Stat5-deficiency has no impact on disease latency and the lymphoid phenotype. The phenotype of FLT3-TKD+ and FLT3-ITD+ Stat5del/del mice is remarkably similar, suggesting that the downstream signaling pathways activated by both types of mutations are also similar with the exception of STAT5.Interestingly, STAT5 activation is stronger in sorted myeloid progenitors compared to lymphoid progenitors expressing FLT3-ITD. These cells also show increased expression of the STAT5 target genes Oncostatin M (OSM), c-Myc and Bcl-2, confirming the cell-type specific signaling of FLT3-ITD in hematopoietic progenitor cells. Moreover, myeloid progenitors - unlike lymphoid progenitors - express significant amounts of c-Src, thereby mediating the activation of STAT5 exclusively in the myeloid compartment. Notably, only bone marrow cells derived from Stat5+/Flt3-ITD+ mice reveal marked upregulation of OSM. Strikingly, Osm expression is sufficient to induce a myeloid disease together with FLT3-D838Y, indicating that the expression of this STAT5 target gene substitutes for the lack of STAT5 activation by FLT3-D838Y.The findings described here provide a rationale for the validation of STAT5 inhibition in FLT3-ITD+, but not FLT3-D835Y+ AML. Additionally, the present study has proven the relevance of OSM for the induction of a myeloid phenotype in mice, justifying further investigations to validate OSM and OSMR as clinical relevant targets in AML and MPN patients with an active STAT5
    Note: Dissertation Albert-Ludwigs-Universität Freiburg 2016
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    [Freiburg] : [Albert-Ludwigs-Universität Freiburg | Hannover : Technische Informationsbibliothek (TIB)
    UID:
    (DE-603)493270752
    Format: 1 Online-Ressource (14 Seiten, 194,24 KB)
    Note: Unterschiede zwischen dem gedruckten Dokument und der elektronischen Ressource können nicht ausgeschlossen werden
    Language: German
    Keywords: Forschungsbericht
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    UID:
    (DE-101)1334464545
    Format: Online-Ressource
    Content: Abstract: Mouse double minute 2 homolog (MDM2) is a negative regulator of the tumor suppressor p53 and is often highly expressed in acute myeloid leukemia (AML) and other solid tumors. Inactivating mutations in TP53, the gene encoding p53, confers an unfavorable prognosis in AML and increases the risk for relapse after allogeneic hematopoietic cell transplantation. We review the concept that manipulation of MDM2 and p53 could enhance immunogenicity of AML and solid tumor cells. Additionally, we discuss the mechanisms by which MDM2 and p53 regulate the expression of major histocompatibility complex class I and II, transcription of double stranded RNA of endogenous retroviruses, responses of interferons, production of interleukin-15, and expression of tumor necrosis factor–related apoptosis–inducing ligand receptor 1 and 2 on malignant cells. The direct effects of MDM2 inhibition or MDM2 deletion in effector T cells are discussed in the context of cancer immunotherapy. The preclinical findings are connected to clinical studies using MDM2 inhibition to enhance antitumor immunity in patients. This review summarizes current evidence supporting the use of MDM2 inhibition to restore p53 as well as the direct effects of MDM2 inhibition on T cells as an emerging concept for combined antitumor immunotherapy against hematological malignancies and beyond
    Note: Blood journal. - 143, 26 (2024) , 2701-2709, ISSN: 1528-0020
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    UID:
    (DE-101)1120020980
    Format: Online-Ressource
    Content: Zusammenfassung: Activating mutations of Fms-like tyrosine kinase 3 (FLT3) are among the most frequent alterations in acute myeloid leukemia (AML). Two distinct types of mutations have been described: internal duplication of the juxtamembraneous domain (ITD) and point mutations of the tyrosine kinase domain (TKD). Although both mutations lead to constitutive FLT3 signaling, only FLT3-ITD strongly activates STAT5. In a murine transplantation model, FLT3-ITD induces a myeloproliferative neoplasm (MPN), while FLT3-TKD leads to a lymphoid disease with significantly longer latency. In the present study it should be examined, to which extent STAT5 has a role for the induction and phenotype of the MPN in the murine model. Furthermore, it should be addressed whether cell-type specific STAT5 signaling in myeloid, but not lymphoid progenitors is responsible for the FLT3-ITD-mediated myeloid expansion in mice and humans.In an initial in vitro experiment, STAT5 was found to be critical for the colony formation of FLT3-ITD+, but not FLT3-TKD+ fetal liver cells. These results were further confirmed in a conditional murine knockout model of Stat5, where the development of a myeloproliferative disease by FLT3-ITD is also dependent on STAT5. In case of the FLT3-TKD-induced disease, Stat5-deficiency has no impact on disease latency and the lymphoid phenotype. The phenotype of FLT3-TKD+ and FLT3-ITD+ Stat5del/del mice is remarkably similar, suggesting that the downstream signaling pathways activated by both types of mutations are also similar with the exception of STAT5.Interestingly, STAT5 activation is stronger in sorted myeloid progenitors compared to lymphoid progenitors expressing FLT3-ITD. These cells also show increased expression of the STAT5 target genes Oncostatin M (OSM), c-Myc and Bcl-2, confirming the cell-type specific signaling of FLT3-ITD in hematopoietic progenitor cells. Moreover, myeloid progenitors - unlike lymphoid progenitors - express significant amounts of c-Src, thereby mediating the activation of STAT5 exclusively in the myeloid compartment. Notably, only bone marrow cells derived from Stat5+/Flt3-ITD+ mice reveal marked upregulation of OSM. Strikingly, Osm expression is sufficient to induce a myeloid disease together with FLT3-D838Y, indicating that the expression of this STAT5 target gene substitutes for the lack of STAT5 activation by FLT3-D838Y.The findings described here provide a rationale for the validation of STAT5 inhibition in FLT3-ITD+, but not FLT3-D835Y+ AML. Additionally, the present study has proven the relevance of OSM for the induction of a myeloid phenotype in mice, justifying further investigations to validate OSM and OSMR as clinical relevant targets in AML and MPN patients with an active STAT5
    Note: Dissertation Albert-Ludwigs-Universität Freiburg 2016
    Language: English
    Keywords: Hochschulschrift
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Book
    Book
    [Freiburg] : [Albert-Ludwigs-Universität Freiburg, Institut für Molekulare Medizin und Zellforschung]
    UID:
    (DE-627)1002654327
    Format: 14 Blätter
    Note: Förderkennzeichen BMBF 0316184D. - Verbund-Nummer 01132245 , Unterschiede zwischen dem gedruckten Dokument und der elektronischen Ressource können nicht ausgeschlossen werden
    Additional Edition: Erscheint auch als Online-Ausgabe Brummer, Tilman, 1970 - OncoPATH - Abschlussbericht [Freiburg] : [Albert-Ludwigs-Universität Freiburg, Institut für Molekulare Medizin und Zellforschung], 2017
    Language: German
    Keywords: Darmkrebs ; Pathophysiologie ; Zelllinie ; Onkogen ; Signalkette ; Proteomanalyse ; Molekulare Medizin ; Forschungsbericht
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    [Freiburg] : [Albert-Ludwigs-Universität Freiburg, Institut für Molekulare Medizin und Zellforschung]
    UID:
    (DE-627)1008620084
    Format: 1 Online-Ressource (14 Seiten, 194,24 KB)
    Note: Förderkennzeichen BMBF 0316184D. - Verbund-Nummer 01132245 , Unterschiede zwischen dem gedruckten Dokument und der elektronischen Ressource können nicht ausgeschlossen werden
    Additional Edition: Erscheint auch als Druck-Ausgabe Brummer, Tilman, 1970 - OncoPATH - Abschlussbericht [Freiburg] : [Albert-Ludwigs-Universität Freiburg, Institut für Molekulare Medizin und Zellforschung], 2017
    Language: German
    Keywords: Darmkrebs ; Pathophysiologie ; Zelllinie ; Onkogen ; Signalkette ; Proteomanalyse ; Molekulare Medizin ; Forschungsbericht
    URL: Volltext  (kostenfrei)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    UID:
    (DE-603)520510984
    Format: 1 Online-Ressource
    Content: Abstract: Mouse double minute 2 homolog (MDM2) is a negative regulator of the tumor suppressor p53 and is often highly expressed in acute myeloid leukemia (AML) and other solid tumors. Inactivating mutations in TP53, the gene encoding p53, confers an unfavorable prognosis in AML and increases the risk for relapse after allogeneic hematopoietic cell transplantation. We review the concept that manipulation of MDM2 and p53 could enhance immunogenicity of AML and solid tumor cells. Additionally, we discuss the mechanisms by which MDM2 and p53 regulate the expression of major histocompatibility complex class I and II, transcription of double stranded RNA of endogenous retroviruses, responses of interferons, production of interleukin-15, and expression of tumor necrosis factor–related apoptosis–inducing ligand receptor 1 and 2 on malignant cells. The direct effects of MDM2 inhibition or MDM2 deletion in effector T cells are discussed in the context of cancer immunotherapy. The preclinical findings are connected to clinical studies using MDM2 inhibition to enhance antitumor immunity in patients. This review summarizes current evidence supporting the use of MDM2 inhibition to restore p53 as well as the direct effects of MDM2 inhibition on T cells as an emerging concept for combined antitumor immunotherapy against hematological malignancies and beyond
    Note: Blood journal. - 143, 26 (2024) , 2701-2709, ISSN: 1528-0020
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    UID:
    (DE-101)1298437776
    Format: Online-Ressource
    Content: Abstract: Pediatric low-grade gliomas (pLGG) show heterogeneous responses to MAPK inhibitors (MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify patients likely to benefit from MAPKi therapy. Here, we identify MAPK-related genes enriched in MAPKi-sensitive cell lines using the GDSC dataset and apply them to calculate class-specific MAPKi sensitivity scores (MSSs) via single-sample gene set enrichment analysis. The MSSs discriminate MAPKi-sensitive and non-sensitive cells in the GDSC dataset and significantly correlate with response to MAPKi in an independent PDX dataset. The MSSs discern gliomas with varying MAPK alterations and are higher in pLGG compared to other pediatric CNS tumors. Heterogenous MSSs within pLGGs with the same MAPK alteration identify proportions of potentially sensitive patients. The MEKi MSS predicts treatment response in a small set of pLGG patients treated with trametinib. High MSSs correlate with a higher immune cell infiltration, with high expression in the microglia compartment in single-cell RNA sequencing data, while low MSSs correlate with low immune infiltration and increased neuronal score. The MSSs represent predictive tools for the stratification of pLGG patients and should be prospectively validated in clinical trials. Our data supports a role for microglia in the response to MAPKi
    Note: Nature Communications. - 14 (2023) , 4533, ISSN: 2041-1723
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages